Delayed clearance of hepatitis B surface antigen and development of hepatitis B surface antibody in a chronic hemodialysis patient
The introduction of hepatitis B vaccination and infection control in 1977 has greatly decreased the prevalence of hepatitis B. Currently, approximately 2.8% of the end-stage renal disease population is hepatitis B positive with a presence in 27.7% of the USA hemodialysis (HD) units according to the...
Main Authors: | Richard Treger, Ramy M Hanna, Brian M Lee, Eduardo A Lopez, James Wilson, Dalila Corry |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2016-01-01
|
Series: | Saudi Journal of Kidney Diseases and Transplantation |
Online Access: | http://www.sjkdt.org/article.asp?issn=1319-2442;year=2016;volume=27;issue=5;spage=1047;epage=1051;aulast=Treger |
Similar Items
-
Hepatitis B surface antigen and antibody to hepatitis B surface antigen^^ in cerebrospinal fluid
by: LIU, JIN-KUAN, et al.
Published: (1986) -
Studies with Hepatitis-B Surface Antigen and its Antibody
by: Islam, M. N.
Published: (1976) -
Serum anti-hepatitis B surface antigen in hemodialysis patients
by: Rafieian-Kopaei Mahmoud, et al.
Published: (2012-01-01) -
Quantitative of serum hepatitis B core antibody is a potential predictor of recurrence after interferon-induced hepatitis B surface antigen clearance
by: Yali Wu, et al.
Published: (2021-04-01) -
Clinical features of chronic hepatitis B patients with low hepatitis B surface antigen levels and determinants of hepatitis B surface antigen seroclearance
by: Hideaki Taniguchi, et al.
Published: (2020-08-01)